Gilead Sciences (NASDAQ:GILD) updated its FY 2020
After-Hours earnings guidance on Thursday. The company provided earnings per share guidance of 6.25-7.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.71. The company issued revenue guidance of $23-25 billion, compared to the consensus revenue estimate of $23.44 billion.Gilead Sciences also updated its FY20 guidance to $6.25-7.65 EPS.
A number of research analysts have recently commented on GILD shares. Jefferies Financial Group reissued a buy rating and issued a $97.00 target price on shares of Gilead Sciences in a report on Tuesday, July 21st. JPMorgan Chase & Co. reissued a hold rating and issued a $85.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 28th. Morgan Stanley cut their target price on shares of Gilead Sciences from $80.00 to $79.00 and set an equal weight rating on the stock in a research report on Friday. SunTrust Banks upped their price target on shares of Gilead Sciences from $73.00 to $74.00 and gave the stock a hold rating in a report on Friday. Finally, Needham & Company LLC reiterated a hold rating on shares of Gilead Sciences in a research note on Tuesday, June 30th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and nine have given a buy rating to the stock. Gilead Sciences currently has an average rating of Hold and a consensus target price of $79.63.
NASDAQ:GILD opened at $69.53 on Friday. The firm’s fifty day moving average is $75.47 and its 200-day moving average is $73.57. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.92 and a current ratio of 3.04. Gilead Sciences has a 52 week low of $60.89 and a 52 week high of $85.97. The firm has a market cap of $87.22 billion, a P/E ratio of -289.70, a P/E/G ratio of 2.34 and a beta of 0.70.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.46). The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.24 billion. Gilead Sciences had a positive return on equity of 32.17% and a negative net margin of 1.16%. As a group, sell-side analysts anticipate that Gilead Sciences will post 6.79 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.91%. Gilead Sciences’s dividend payout ratio is 44.30%.
In other Gilead Sciences news, Director John Francis Cogan sold 2,416 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $81.75, for a total value of $197,508.00. Following the transaction, the director now directly owns 57,276 shares of the company’s stock, valued at $4,682,313. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Diane E. Wilfong sold 12,264 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $80.09, for a total value of $982,223.76. Following the transaction, the chief accounting officer now owns 23,685 shares in the company, valued at $1,896,931.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,079 shares of company stock worth $2,240,630. 0.13% of the stock is owned by corporate insiders.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: What is meant by buying and selling pressure?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.